Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 1 AL 15

Plant-derived phytochemicals for Alzheimer's disease: mechanisms of action, experimental evidence, and therapeutic perspectives

Nimbalkar J, Shinde R.

J Nat Med. 2026 Nov;80(6):1575-1610. doi: 10.1007/s11418-026-02090-x. Epub 2026 Oct 8.

Dysregulated metal homeostasis in Alzheimer's disease: From pathological modulators to therapeutic targets

Yang J, Lou F, Sun W, Li M, Su L, Wang Y, Li P, Su J.

Pharmacol Res. 2026 Nov;233:109690. doi: 10.1016/j.phrs.2026.109690. Epub 2026 Oct 17.

Plasma Angiotensin-Converting Enzyme as a Prioritized Candidate Target for Alzheimer's Disease: Evidence From Proteome-Wide Mendelian Randomization and a Large Prospective Cohort Study

Huang P, Tang H, Feng Z, Stergiakouli E, Gaunt TR, Zheng J, Lu Y.

J Am Heart Assoc. 2026 Nov 3;15(21):e038766. doi: 10.1161/JAHA.124.038766. Epub 2026 Oct 23.

Case Report: Longitudinal evaluation of cerebrospinal fluid Alzheimer's disease core biomarkers in a case of refractory late-onset epilepsy of unknown etiology

Wada T, Kuzuya A, Koda K, Ueda S, Shima A, Sawamoto N, Ikeda A, Takahashi R, Matsumoto R.

Front Aging Neurosci. 2026 Oct 12;18:1807027. doi: 10.3389/fnagi.2026.1807027. eCollection 2026.

Research progress on terpenoids alleviating Alzheimer's disease through the Keap1/Nrf2/ARE pathway by exerting antioxidant effects and promoting mitophagy

Zhang W, Wang S, Gou X.

J Alzheimers Dis. 2026 Oct;113(4):1539-1554. doi: 10.1177/13872877261480043. Epub 2026 Aug 31.

Efficacy and safety of aducanumab, lecanemab, and donanemab in Alzheimer's disease: A meta-analysis of randomized controlled trials

Ali M, Shabbir H, Shaharyar M, Mukesh S, Rodriguez A, Afshani M, Kalra D, Koriesh A.

J Alzheimers Dis. 2026 Sep 28:13872877261488812. doi: 10.1177/13872877261488812. Online ahead of print.

From bench to beside: luteolin's therapeutic promise in neurological disorders

Zhu W, Yuan N, Tang M, She K, Chen M, Huang M, Feng R, Ma Q, Chen J.

Chin J Nat Med. 2026 Oct;24(10):1153-1162. doi: 10.1016/S1875-5364(26)61211-3.

The efficacy of donepezil combination therapy strategies in Alzheimer's disease: A systematic review and network meta-analysis

Ning X, Xiao Y, Wang N, Jiao X, Li X, Zhang Y, Zhao Q.

J Alzheimers Dis. 2026 Sep 30:13872877261491977. doi: 10.1177/13872877261491977. Online ahead of print.

Advances in Extracellular Vesicle-Based Innovative Drugs Targeting Alzheimer's Disease

Liu S, Lu J, Liu J, Liu H, Liu Z, Yang D, Liang X, Xu J.

Mol Neurobiol. 2026 Oct 7;63(1):954. doi: 10.1007/s12035-026-06223-x.

Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer's disease: a systematic review and meta-analysis

Li SY, Zhang JX, Huang LZ, Wu HB, Ye YB, Liu A, Chen J, Lai S.

Front Pharmacol. 2026 Sep 28;17:1947129. doi: 10.3389/fphar.2026.1947129. eCollection 2026.

Targeting the P2X7 receptor in Alzheimer's disease: mechanistic insights and emerging therapeutic strategies

Se ME, Ramalingam A.

Purinergic Signal. 2026 Oct 15;22(5):79. doi: 10.1007/s11302-026-10191-1.

Synergistic approaches to Alzheimer's disease: exploring the combined efficacy of phytoconstituents and conventional drugs

Kumar A.

Inflammopharmacology. 2026 Oct 14. doi: 10.1007/s10787-026-02417-w. Online ahead of print.

Targeting Specific Sirtuin Modulation: Emerging Therapeutic Strategies for Healthy Cognitive Ageing and Potential Implications for Alzheimer's Disease

McDermott C, Cole MH, Pearson M, Winberg P, Fernandez F.

Molecules. 2026 Oct 3;31(19):3528. doi: 10.3390/molecules31193528.

Lecanemab-Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease

Cutler J, Tran BA, Bullers K, Fox C.

J Pharm Technol. 2026 Oct 14:87551225261492568. doi: 10.1177/87551225261492568. Online ahead of print.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias